
Open innovation

Patients as catalysts for change

Closing the Feedback Loop

Can Technology Bridge the Accountability Gap?

Björn-Sören Gigler and Savita Bailur, Editors



Source: Samantha Custer, adapted from Custer, Novin, and Palumbo 2011.

CONCEPTS

- Citizen feedback loop (sharing information, giving feedback, tacking action): successful planning, management & evaluation of development projects
- Citizen participation: understanding citizenship as 'the rights and responsibilities' of individuals (Aristotles); participation is not mere 'accountability', it implies 'ownership' of projects.
- Civic engagement: civic society as 'the multiple organizations buffering between citizens and the state, including political parties, news media, traditional interest groups [...]' (Norris, 2003)





SICPA Contributes to a World Bank Pilot Project to Fight Falsified and Sub-Standard Medicines

WASHINGTON, October 28, 2014

Marking a further step in the cooperation between SICPA and International Organizations, Anne-Marie Leroy, Senior Vice President and General Counsel of the World Bank Group, and Pierre Viaud, Senior Director Public Affairs & Government Relations of SICPA, signed during the Law, Justice and Development Week 2015 an agreement confirming SICPA's contribution to a Pilot Project developed by the Global Forum on Law, Justice and Development (GFLJD).



An open innovation system for rare diseases in Brazil

Towards a bottom-up approach with patients as innovators

Agenda

1	Healthcare delivery in Brazil
2	Rare diseases
3	Open innovation
4	Solution
5	Strengths and limitations

General problem


Low demand
Rare diseases =

Poor access to specialized healthcare

Σ

Physical (hospitals, clinics and other facilities)
Treatments, diagnostic tests and technologies

Public policies



Rare diseases

- 13 million people (+ São Paulo, New York, L.A.)
- February 2014: first comprehensive national policy for rare diseases
- The SUS will incorporate 15 new tests to diagnose rare diseases and accredit hospitals and institutions for the care of patients suffering from these diseases



DISEASES


Addison's Disease Congenital Adrenal hyperplasia Congenital Hypothyroidism Crohn's Disease Cystic Fibrosis of the Pancreas Pulmonary Cystic Fibrosis Gaucher's Disease Hereditary Angioedema Hereditary ichthyosis Hypoparathyroidism Hypopituitarism Myasthenia Gravis Multiple Sclerosis Phenylketonuria Sickle Cell Disease Turner's Syndrome Wilson's desease Etc.

Source: Interfarma, April 2013

Open innovation

- Health 2.0 is the use of Internet or Web 2.0-based technology in health care (Van De Belt et al. 2010)
- The innovation potential of Health 2.0 is still under-researched
- User participation, openness and network effects

Open innovation system (Chesbrough, 2003) that may leverage the participatory practices already promoted by the Brazilian Federal Government in order to strengthen the public provision of health care for rare diseases in conjunction with the patients and other stakeholders, optimizing resources, improving access and quality of health care



Solution

- Community for patients and affected people of rare diseases that will connect them to a multitude of possible problem solvers like caregivers, researchers, engineers, other patients, and policy makers
- Two focuses: 1) Information dissemination and social support and 2) Innovation creation –incremental and radical- (market place for exchanging ideas)
- It should start as a pilot, scalable to other Portuguese-speaking countries (+220 million native speakers)
- Inspired by the model of GemeinsamSelten (Rarely Together), launched in 2011



Strenghts and limitations

STRENGHTS

- The pilot is open to further technological sophistication: i.e. private optical fiber network for connecting research centers, protecting confidential information; biometric identification of the users, digital signature, m-apps, etc.
- It generates demand, previously fragmented
- The supply side would be incentivized (on-line marketplace)
- It overcomes market failures and information asymmetries
- Peer supervision
- Collaborative solutions can be customized and developed faster (R&D)
- Commonalities among different diseases can be found
- Institutional support and awareness about real needs
- Generation of local knowledge
- Easy replicability
- Positive synergies as a result of a high degree of interaction and user's motivation

LIMITATIONS

- Brazilian law bans doctor-to-patient solutions; it only allows doctor-to-doctor consultations
- Privacy concerns
- Systemic inefficiencies in the health system
- Funding
- Incentives to actively participate and ensure adherence
- Intuitive, user-friendly
- Poor infrastructures (no access to broadband) in some areas
- M&E before scaling up the solution

Thank you